FDA panel recommends Pfizer’s epoetin alfa biosimilar to treat anemia
The committee has recommended the approval based on its assessment of the totality of evidence, comprising of showing comparable efficacy and safety of biosimilar epoetin alfa to its
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.